MorphImmune
West Lafayette
About MorphImmune
Morphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases the efficacy of known effector molecules, ultimately improving outcomes for patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $32.1M
- Funding stage: M&A
- Last round: Series Unknown (May 2023)
- Website: morphimmune.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/morphimmune-120616 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.